Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT06928675 (CANTO) for Stroke is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Cell-free DNA in Acute Stroke (CANTO) 200
Clinical Trial NCT06928675 (CANTO) is an observational study for Stroke that is recruiting. It started on March 30, 2025 with plans to enroll 200 participants. Led by University Hospital, Basel, Switzerland, it is expected to complete by September 1, 2026. The latest data from ClinicalTrials.gov was last updated on April 15, 2025.
Brief Summary
Cell-free DNA (cfDNA) is an important pro-inflammatory and prothrombotic mediator. With this study the investigators aim to gain new insights into the role of cfDNA in stroke and to perform a combined analysis of cfDNA in the hyperacute phase of the disease using blood and thrombus analyses. The main objectives are to analyse cfDNA in different stroke etiologies, to investigate the relationship between cfDNA and impo...Show More
Official Title
CANTO - Cell-free DNA in Acute Stroke
Conditions
strokeOther Study IDs
- CANTO
- 2025-00235; ko24grosse2
NCT ID Number
Start Date (Actual)
2025-03-30
Last Update Posted
2025-04-15
Completion Date (Estimated)
2026-09-01
Enrollment (Estimated)
200
Study Type
Observational
Status
Recruiting
Keywords
cell-free DNA
stroke etiologies
reperfusion
secondary emboli
stroke subtypes
stroke etiologies
reperfusion
secondary emboli
stroke subtypes
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Stroke Etiology | Descriptive comparison of cell-free DNA in cerebral thrombi regarding stroke etiology | at day 1 |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Correlation cfDNA concentration and perfusion outcome | cfDNA abount in blood and thromi is assessed in relation to thrombectomy outcomes including perfusion outcome | at day 1 |
Correlation cfDNA concentration and secondary embolism | cfDNA abount in blood and thromi is assessed in relation to thrombectomy outcomes including secondary embolism | at day 1 |
Correlation cfDNA concentration and thrombus fragmentation. | cfDNA abount in blood and thromi is assessed in relation to thrombectomy outcomes including thrombus fragmentation | at day 1 |
Measures of cfDNA as a marker of systemic inflammation | to correlate cfDNA amount in blood and thrombi | at day 1 |
90-day functional outcomes | to examine the association between cfDNA concentrations in blood and thrombi with 90-day functional outcomes.
To assess functional outcomes, the modified Rankin Scale (mRS) is evaluated via a structured telephone interview on day 90. A favorable outcome is defined as an mRS score of 0 to 2 points, while an unfavorable outcome is defined as an mRS score of 3 to 5 points. | up to 3 month |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
- Acute ischemic stroke due to large vessel occlusion (LVO) who require mechanical thrombectomy (detected in CT-Scan or MRI-Scan)
- 18 years of age
- Patients currently undergoing immunological therapies.
- Patients with immunological diseases
- Patients with systemic infections at the time of admission
University Hospital, Basel, SwitzerlandStudy Central Contact
Contact: Gerrit Grosse, PD Dr. Dr., +41 61 32 85265, [email protected]
1 Study Locations in 1 Countries
University Hospital Basel, Basel, 4031, Switzerland
Gerrit Grosse, PD Dr. Dr., Contact, +41 61 32 85265, [email protected]
Gerrit Grosse, PD Dr. Dr., Principal Investigator
Recruiting